STOCK TITAN

Regenxbio Inc - RGNX STOCK NEWS

Welcome to our dedicated news page for Regenxbio (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regenxbio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regenxbio's position in the market.

Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 29, 2024. The event includes a Fireside Chat at 10:30 a.m. EDT and a panel on Gene Therapy at 4:00 p.m. EDT. The live webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences
-
Rhea-AI Summary
REGENXBIO Inc. announces positive results from the Phase I/IIa trial of ABBV-RGX-314 gene therapy for wet AMD, showing stable or improved vision and retinal anatomy up to 4 years. The treatment aims to become a new standard-of-care option with potential multi-billion-dollar value, supporting global regulatory submissions in late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. (RGNX) will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on April 3, 2024. The fireside chat will be held at 9:50 a.m. EDT. Investors can access the live webcast on REGENXBIO's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences
Rhea-AI Summary
REGENXBIO Inc. (RGNX) is set to participate in several investor conferences, including Leerink Partners 2024 Global Biopharma Conference and Barclays 26th Annual Global Healthcare Conference. The company will also be part of the UBs Virtual CNS Day. Investors can access a live webcast of the fireside chat at the Barclays conference on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences
-
Rhea-AI Summary
REGENXBIO Inc. announces the pricing of an underwritten upsized public offering, expecting to raise approximately $140.0 million. The offering includes 4,565,260 shares of common stock and 1,521,740 pre-funded warrants. The company has granted the underwriters an option to purchase an additional 913,050 shares. The offering is expected to close on March 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. (RGNX) plans to offer $125 million of its common stock in a public offering, with underwriters having a 30-day option to purchase additional shares. The offering is subject to market conditions, and the final terms will be disclosed in a prospectus supplement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
Rhea-AI Summary
REGENXBIO Inc. reports positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 for Duchenne muscular dystrophy. Notable findings include robust microdystrophin expression, strength and motor function improvements, and encouraging safety profiles. The company plans to initiate a pivotal trial in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.22%
Tags
none
-
Rhea-AI Summary
REGENXBIO Inc. (RGNX) will host a webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 for Duchenne muscular dystrophy. The primary investigator, Aravindhan Veerapandiyan, M.D., will present the data on March 5, 2024. Additionally, Dr. Veerapandiyan will present at the MDA Clinical & Scientific Conference on March 6, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.5%
Tags
conferences clinical trial
-
Rhea-AI Summary
REGENXBIO Inc. announces financial results for Q4 2023, highlighting progress on AAV Therapeutic product candidates. The company plans pivotal trials and BLA filing in 2024, with $314 million in cash to fund operations until H2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
Rhea-AI Summary
REGENXBIO Inc. (RGNX) will host a conference call to discuss its Q4 and full-year 2023 financial results and recent operational highlights on February 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
conferences earnings
Regenxbio Inc

Nasdaq:RGNX

RGNX Rankings

RGNX Stock Data

887.18M
37.36M
7.18%
81.62%
8.05%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Rockville

About RGNX

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.